The role of blood services and regulatory bodies in stem cell transplantation.
Advances in stem cell research over the past few decades have coincided with large increases in haemopoietic stem cell transplantation (HSCT) using either bone marrow, peripheral blood or cord blood-derived stem cells. Alongside this growth has come an increase in the role played by regulatory bodies, both governmental and professional, to ensure that those undertaking such procedures do so in a manner so as to minimize the risk to patients. Interestingly, government legislation encompasses not only cellular therapies, but also the use of tissues and organs, as many of the processes and procurement procedures involved are similar. In this review, we analyse the trends in HSCT, describe the development and impact of legislation within Europe on this practice and outline the vital role played by the UK blood services in providing robust and high-quality HSCT services.
Austin
E B
EB
Stem Cells and Immunotherapies, National Blood Service - Manchester, National Health Service Blood and Transplant, Manchester, UK. eric.austin@nbs.nhs.uk
Guttridge
M
M
Pamphilon
D
D
Watt
S M
SM
D001771:Blood Banks / Q000331:legislation & jurisprudence / Q000592:standards; D005062:European Union; D018380:Hematopoietic Stem Cell Transplantation / Q000266:history / Q000331:legislation & jurisprudence* / Q000592:standards / Q000639:trends; D049673:History, 20th Century; D049674:History, 21st Century; D006801:Humans; D013222:State Medicine / Q000331:legislation & jurisprudence / Q000592:standards; D006113:United Kingdom